Login to Your Account

'We've just scratched the surface'

Six for sixth: Zymeworks lures J&J to potential $1.45B bispecific deal

By Marie Powers
News Editor

Tuesday, November 14, 2017

Zymeworks Inc. nailed down its sixth strategic partnership, luring Johnson & Johnson unit Janssen Biotech Inc. to a potential $1.45 billion global license to research, develop and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks' Azymetric and EFECT (Effector Function Enhancement and Control Technology) platforms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription